Related Experiment Videos
Double-blind multicenter study comparing alprostadil alpha-cyclodextrin with moxisylyte chlorhydrate in patients with
The Journal of Urology
|December 24, 1997
Summary
Alprostadil alpha-cyclodextrin is more effective than moxisylyte chlorhydrate for treating erectile dysfunction, leading to better patient and partner satisfaction. This study highlights its superior efficacy in achieving adequate erections for sexual intercourse.
Area of Science:
- Urology
- Pharmacology
- Sexual Medicine
Background:
- Erectile dysfunction (ED) affects a significant number of men, impacting quality of life.
- Pharmacological interventions are a cornerstone of ED treatment.
- Comparing novel and established treatments is crucial for optimizing patient outcomes.
Purpose of the Study:
- To compare the efficacy and safety of alprostadil alpha-cyclodextrin versus moxisylyte chlorhydrate.
- To evaluate the ability of these agents to induce erections sufficient for sexual intercourse.
Main Methods:
- A prospective, randomized, double-blind, parallel study.
- 156 men with ED were randomized into two treatment groups.
- Erectile response was objectively measured using the buckling test.
Main Results:
- Alprostadil alpha-cyclodextrin demonstrated significantly higher success rates (81% vs. 46%) in achieving adequate erections compared to moxisylyte chlorhydrate.
- Higher patient and partner satisfaction scores were reported with alprostadil alpha-cyclodextrin.
- Both agents showed similar injection-related side effects, but moxisylyte had more systemic effects.
Conclusions:
- Alprostadil alpha-cyclodextrin is significantly more effective than moxisylyte chlorhydrate for inducing penile rigidity.
- Patient and partner satisfaction is significantly higher with alprostadil alpha-cyclodextrin.
- Alprostadil alpha-cyclodextrin offers a superior treatment option for erectile dysfunction.